Sarepta Therapeutics | SRPT - Operating Expenses


Sarepta Therapeutics reported $387.96M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amgen USD 11.69B 6.9B Jun/2026
BioCryst Pharmaceuticals USD 119.78M 673.63M Jun/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Capricor Therapeutics USD 29.16M 2.87M Dec/2025
Daiichi Sankyo JPY 489.64B 21.08B Jun/2026
Eli Lilly USD 10.52B 496M Jun/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
Insmed USD 606.26M 79.46M Sep/2026
Ionis Pharmaceuticals USD 370.24M 6.24M Jun/2026
Moderna USD 960M 817M Jun/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 739.1M 139.2M Jun/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 9.92B 607M Jun/2026
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Tectonic Therapeutic USD 27.3M 5.78M Mar/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026